Sopharma AD-SofiaWAR:SPH +8.49%67 Net Margin % is 8.98% as of Mar. 2026, which is 94% above its 10-year median of 4.62. GuruFocus rates WAR:SPH with a GF Score™ of 67/100 and a GF Value™ of zł13.56 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 119 Medical Distribution companies, Sopharma AD-Sofia ranks better than 77.31% on this metric.
The historical rank and industry rank for Sopharma AD-Sofia's Net Margin % or its related term are showing as below:
WAR:SPH'
s Net Margin % Range Over the Past 10 Years
Min: 2.07 Med: 4.62 Max: 6.79
Current: 5.67
WAR:SPH's Net Margin % is ranked better than 77.31% of 119
companies
in the Medical Distribution industry
Industry Median: 1.53
vs WAR:SPH: 5.67
Sopharma AD-Sofia (WAR:SPH) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Sopharma AD-Sofia Net Margin % Related Terms
Sopharma AD-Sofia Net Margin % Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Sopharma AD-Sofia's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sopharma AD-Sofia Net Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sopharma AD-Sofia's Net Margin % distribution charts can be found below:
* The bar in red indicates where Sopharma AD-Sofia's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (WAR:SPH) has a Net Margin % of 8.98% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Sopharma AD-Sofia and its competitors. This is 94% above median its historical median of 4.62. Over the past decade, Sopharma AD-Sofia's Net Margin % has ranged from 2.07 to 6.79. According to the industry distribution chart, Sopharma AD-Sofia ranks #27 out of 119 companies in the Medical Distribution industry, placing it in the top 22.7%.
Is Sopharma AD-Sofia's Net Margin % too high?
Sopharma AD-Sofia's current Net Margin % of 8.98% is 94% above median its 10-year median of 4.62. Over the past 10 years, this metric has ranged from a low of 2.07 to a high of 6.79. The Medical Distribution industry median Net Margin % is 1.53. Sopharma AD-Sofia's value of 8.98% is 486.9% above this industry median. Based on the distribution chart, Sopharma AD-Sofia ranks #27 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's Net Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #27 out of 119 companies for Net Margin %. This places Sopharma AD-Sofia in the top 23% of its industry — outperforming the majority of peers. The industry median Net Margin % is 1.53. Sopharma AD-Sofia's value of 8.98% is 486.9% above this benchmark. Historically, Sopharma AD-Sofia's own Net Margin % has ranged from 2.07 to 6.79 over the past decade. While the company's 10-year median is 4.62 vs. the industry median of 1.53, Sopharma AD-Sofia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Distribution company?
The median Net Margin % among Medical Distribution companies is 1.53, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sopharma AD-Sofia's current Net Margin % of 8.98% is 486.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median Net Margin % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current Net Margin % is 8.98%, which is 94% above median its own 10-year median of 4.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.56, compared to a current price of zł7.92 — trading 41.6% below its estimated fair value. The current Net Margin % is 8.98%, which is 94% above median its 10-year median of 4.62 and 486.9% above the Medical Distribution industry median of 1.53. Sopharma AD-Sofia's overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current Net Margin % is 8.98% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł7.92 is trading 41.6% below its estimated GF Value™ of zł13.56.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
Net Margin %: 8.98% (94% above median its 10-year median of 4.62)
GF Value™: zł13.56 vs. price of zł7.92 (41.6% below fair value)
Industry Position: 486.9% above the Medical Distribution median (#27 of 119)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
67GF Score
Get the complete analysis for WAR:SPH
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
